# Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

> **NCT04345146** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 100 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** FSRT combined with Bevacizumab

## Key facts

- **NCT ID:** NCT04345146
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345146, "Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04345146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*